GlassScriptPhysician profile
Guadalupe Flores
NPI 1629800230
$5,597.06
in general payments reported to CMS, 2019-2025
27 companies · $5,476 in 2025
The $5,476 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $121 · 2025: $5,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,597.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $819.50 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $542.27 | 2025 | Rezdiffra |
| Lilly USA, LLC | $540.74 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $520.62 | 2025 | Ozempic, Wegovy, Rybelsus |
| Mannkind Corporation | $360.66 | 2025 | |
| Amgen INC. | $356.32 | 2025 | Evenity, Repatha, Tepezza |
| Ascensia Diabetes Care US INC. | $315.71 | 2025 | |
| Dexcom, INC. | $276.26 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $233.18 | 2025 | |
| Recordati_rare_diseases_inc. | $190.16 | 2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $188.25 | 2024-2025 | Strensiq |
| Abbott Laboratories | $158.62 | 2025 | Freestyle Libre, Freestyle Libre 3 |
| Insulet Corporation | $156.24 | 2025 | Omnipod |
| Radius Health, INC. | $154.73 | 2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $139.90 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $135.36 | 2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $120.61 | 2025 | |
| Tandem Diabetes Care, INC. | $120.30 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $48.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $43.56 | 2025 | |
| Esperion Therapeutics, INC. | $38.87 | 2025 | Nexletol |
| Soleno Therapeutics, INC. | $30.44 | 2025 | Vykat Xr |
| Abbvie INC. | $27.19 | 2025 | |
| Neurocrine Biosciences, INC. | $25.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2025 | Jardiance |
| Rhythm Pharmaceuticals, INC. | $16.56 | 2025 | Imcivree |
| Antares Pharma, INC. | $16.26 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guadalupe Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.